Characterization of autoreactive T cells in Guillain-Barré syndrome
Dr. Daniela Latorre, ETHZ
Abstract (Lay summaries see below)
Guillain-Barré syndrome (GBS) is a rare disabling neuromuscular disease that affects the peripheral nervous system (PNS) being characterized by an acute onset, rapid progression of muscle weakness, loss of tendon reflex and sometimes, paralysis. Despite the fact that the first description of the disease occurred more than a century ago, the mechanisms underlying the pathogenesis of GBS remain unclear. A better understanding of the cellular and molecular players involved in the immunopathology of GBS is needed to develop more specific and effective treatments as well as reduce/prevent diseaserelated disability. GBS is thought to be an autoimmune disease where molecular mimicry occurs since evidence suggests that auto-antibodies (auto-Abs), generated by preceding Campylobacter jejuni infection, may attack gangliosides expressed in human peripheral nerves inducing axonal damage. Since the first report describing the involvement of humoral immune response in GBS, most studies have focused on the identification of auto-Abs with different specificities in GBS patients’ sera. However, only a minor fraction of GBS patients has detectable serum auto-Abs, thus suggesting that additional immune-mediated mechanisms may be involved. Nevertheless, the involvement of pathogenic autoreactive T lymphocytes in the etiology of experimental autoimmune neuritis (EAN), the animal model of GBS, together with observations showing T cell infiltration in the peripheral nerves and alteration in T cell activation and cytokine expression in the blood of GBS patients, indicate that autoreactive T cells may exist and contribute to the pathophysiology of the disease in humans. However, a systematic analysis of autoreactive T cells in GBS patients is still lacking.
This project aims at filling this gap by investigating the existence and providing a comprehensive characterization of autoreactive T cells in GBS patients. In this research, I propose to use established approaches as well as to implement new methodologies to study autoreactive T cell response in GBS patients through 3 Objectives: Objective 1 is to explore variations in the frequency and distribution of circulating T cell subsets ex vivo in the blood of GBS patients during different phases of the disease (acute vs recovery phase); Objective 2 is to examine the existence, distribution, T cell receptor (TCR) repertoire as well as the phenotype of self-reactive T cells ex vivo from the blood of GBS patients by combining in vitro T cell culture screenings and highthroughput single cell analysis, such as single cell RNA sequencing and TCR sequencing; Objective 3 is to investigate the molecular mimicry mechanism in GBS by using a novel unbiased approach that combines sequential in vitro screening with TCR sequencing of microbe-specific T cells to study cross-reactive autoimmunity. The outcomes of this project may have a substantial impact in the understanding T cell immunity in GBS, as well as medical implications for the development of new therapeutic options for GBS and, potentially, a larger spectrum of neuromuscular disorders.
Lay summary (italian)
Questo progetto si propone di testare l’ipotesi di un’origine autoimmune della sindrome di Guillain-Barré (GBS), una rara malattia demielinizzante che colpisce il sistema nervoso periferico (PNS) e si sviluppa generalmente in seguito ad infezione microbica. Nonostante la prima descrizione di questa patologia sia avvenuta più di cento anni fa, i meccanismi cellulari e molecolari coinvolti nella sua patogenesi non sono ancora chiari. In questo progetto utilizzeremo nuovi approcci sperimentali che abbiamo recentemente sviluppato per caratterizzare la risposta dei linfociti T contro antigeni espressi dal PNS in pazienti affetti da GBS. Ci aspettiamo che questa ricerca possa espandere significativamente la nostra comprensione di base della funzione delle cellule T nelle risposte autoimmuni e portare allo sviluppo di nuove terapie per curare GBS ma anche un più largo spettro di malattie neuromuscolari.
Lay summary (german)
Der Fokus des Projekts liegt auf dem Guillain-Barré Syndrom (GBS), einer seltenen demyelinisierenden Erkrankung des peripheren Nervensystems (PNS), die sich im Allgemeinen infolge einer mikrobiellen Infektion entwickelt. Es soll der Hypothese nachgegangen werden, dass GBS als Autoimmunkrankheit zu verstehen ist. Obgleich die erste Beschreibung der Erkrankung bereits vor über hundert Jahren erfolgte, sind die zellulären und molekularen Prozesse noch nicht bekannt. In unserem Projekt setzen wir auf neue experimentelle Ansätze, die wir kürzlich entwickelt haben, um die direkte T-Zell-Antwort gegen vom PNS exprimierte Antigene bei GBS-Patienten zu charakterisieren.
Wir erwarten uns von diesem Projekt eine signifikante Erweiterung des grundlegenden Verständnisses der Funktion der T-Zellen in der Autoimmunantwort. Weiterführend sollen die Erkenntnisse der Entwicklung neuer Therapien sowohl von GBS als auch neuromuskulärer Erkrankungen im Allgemeinen dienen.
Progetti
- Nuovi progetti di ricerca dal 2024
- L'importanza della ricerca
- Progetti finanziati
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Opuscolo progetti
- SEAL Therapeutics AG
- Meeting e workshop
- Partecipazione ad altre organizzazioni
- Registri dei pazienti
- La rete Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch